Navigation Links
Breast Cancer Vaccine Blasts Some Tumors
Date:9/15/2008

In animal studies, it eliminated aggressive growths

MONDAY, Sept. 15 (HealthDay News) -- An experimental breast cancer vaccine eliminated tumors in laboratory animals and may someday help prevent cancer recurrence or help treat women with treatment-resistant forms of breast cancer.

"The results were striking," said study author Dr. Wei-Zen Wei, a professor of immunology and microbiology at the Karmanos Cancer Center at Wayne State University. The research was published in the Sept. 15 issue of Cancer Research.

Wei's vaccine targets HER2-positive tumor cells. These breast cancers are often more aggressive than other types of cancer, are less responsive to treatment with hormones, and can become resistant to treatment.

On a cellular level, HER2 receptors promote normal cell growth, Wei explained. They are found in low amounts in normal breast cells, but HER2-positive breast cells can have many more receptors, and that in turn can promote the growth of an aggressive type of tumor.

Even therapies such as Herceptin (trastuzumab), designed to hook up with these receptors and destroy them, sometimes work only for a short period of time, after which patients develop a resistance, and the drug stops working.

Enter the study of Wei's vaccine, which includes "naked" DNA, genes that produce the HER2 receptor, and an immune system stimulant. When she delivered the vaccine into the leg muscles of mice with HER2-positive tumors, the gene made a huge supply of HER2 receptors that activated the immune system.

After the injection, "the body is making in this one location a lot of HER2," she said. The immune system kicks in and mounts an attack against the HER2-positive receptors, she found.

''None of them grew tumors," Wei said. That was true whether or not the tumor cells had grown drug-resistant or not.

The investigational vaccine, one of several under study for breast cancer, looks "potentially valuable," said Dr. Minetta Liu, director of translational breast cancer research at Lombardi Comprehensive Cancer Center at Georgetown University in Washington, D.C.

"This [vaccine] is a little unique," she said. "It may help restore drug sensitivity to tumor cells." Of the research, she said: "It's valuable research, potentially groundbreaking."

"What they are doing is providing a different kind of immune response," added Dr. Bill Chambers, scientific program director for the American Cancer Society. Often a vaccine works by directly stimulating the production of antibodies, which then attack what's perceived as a foreign invader. "Instead of inducing the production of antibodies, it induces the development of cells that directly kill the tumor," Chambers said. "It's a very useful observation."

Much more research is needed to determine if the findings will bear out and apply to humans, Liu said.

More information

To learn more about cancer vaccines, visit the American Cancer Society.



SOURCES: Wei-Zen Wei, Ph.D., professor, immunology and microbiology, Karmanos Cancer Institute, Wayne State University, Detroit; Minetta Liu, M.D., assistant professor, medicine, and director, translational breast cancer research, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, D.C.; Bill Chambers, Ph.D., scientific program director, American Cancer Society, Atlanta; Sept. 15, 2008, Cancer Research


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Risk of breast cancer mutations underestimated for Asian women, Stanford study shows
2. Pennsylvania Breast Cancer Coalition Hosts Annual Conference
3. Breast cancer screening may lower mortality and disease burden in India
4. Eating fish while pregnant, longer breastfeeding, lead to better infant development
5. Formula Samples Hinder Breast-Feeding Efforts
6. Yoplait(R) Celebrates 10th Anniversary of Save Lids to Save Lives(R) and Sustained Commitment to Fight Against Breast Cancer
7. Drug Re-Sensitizes Breast Tumors to Treatment
8. Breast Cancer Drug Not Tied to Cognitive Decline: Study
9. Hospitals provide formula sample packs while medical organizations encourage breastfeeding
10. Komen Travels to Republican Convention to Raise Awareness of Breast Cancer Issues
11. Superbug breast infections controllable in nursing mothers, UT Southwestern researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Breast Cancer Vaccine Blasts Some Tumors
(Date:9/19/2017)... ... September 19, 2017 , ... ... its executive team as the President of its HealthBI division. McFarland will ... and contact centers. , “Scott is a utility player who balances his ...
(Date:9/19/2017)... ... September 19, 2017 , ... MelaKids, a Laredo-based company, has introduced a ... When we’re born, Nature gives us a full supply of melanin – in the ... lose this natural glare-reducing pigment; however, around the age of thirty, we develop a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... the present, Mirixa Corporation recently unveiled the MirixaPro 6.0 platform. As the ... how medication management services are delivered. Based on industry research and market ...
(Date:9/19/2017)... ... September 19, 2017 , ... Back Pain Centers of ... back pain with a reputable physician in their area, announces the addition of ... as Nevada Spine Clinic was founded by board-certified spine surgeon, Jaswinder Grover, M.D. ...
(Date:9/19/2017)... ... 2017 , ... The ISO 9001 standard sets out the requirements for a ... and improve customer satisfaction. ISO 9001:2015 was released in 2015 and certified organizations have ... September 2018. , As described in this white paper , ISO ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... , Sept. 12, 2017  ValGenesis Inc., the ... (VLMS), is pleased to announce the appointment of ... of its Board of Directors and Chairman of ... enables life science companies to manage their entire ... of paper in this process. Furthermore, ValGenesis VLMS ...
(Date:9/9/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... lasmiditan, an investigational, oral, first-in-class molecule for the acute ... to placebo in the Phase 3 SPARTAN study. Detailed ... of the International Headache Society (IHC) in ... demonstrate lasmiditan,s potential to reduce pain and provide freedom ...
(Date:9/7/2017)... Caris Life Sciences, a leading innovator ... of precision medicine, today announced results from two ... molecular profiling approach in guiding therapeutic strategies in ... (CGP+) with Caris Molecular Intelligence ® to ... level, leading to more therapeutic options and improved ...
Breaking Medicine Technology: